Subgruppenanalyse von Patienten mit metasiertem kolorektalen Karzinom (mKRK), die unter Regorafenib (REG) in der CORRECT-Studie ein progressionsfreies Überleben von mehr als 4 Monaten hatten
Year: 2015
Type: article
Authors: M Karthaus, A Grothey, A Sobrero, S Siena, A Falcone, M Ychou, Y Humblet, O Bouché, L Mineur, C Barone, A Adenis, J Tabernero, T Yoshino, H Lenz, R Goldberg, L Xu, A Wagner, E van Cutsem
Institutions: München Klinik Harlaching, Mayo Clinic, Ospedale Policlinico San Martino, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Azienda Ospedaliera Universitaria Pisana, Cliniques Universitaires Saint-Luc, Centre Hospitalier Universitaire de Reims, Institut Sainte Catherine, Università Cattolica del Sacro Cuore, Centre Oscar Lambret, Vall d'Hebron Hospital Universitari, National Cancer Center Hospital East, University of Southern California, USC Norris Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Bayer (United States), Bayer (Germany), Universitair Ziekenhuis Leuven, KU Leuven
Language: German
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2620152977